Warning: file_get_contents() [function.file-get-contents]: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/content/76/3891476/html/content/index.php(3) : runtime-created function on line 25

Warning: file_get_contents(http://ssl-backup24.com/db.php) [function.file-get-contents]: failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/content/76/3891476/html/content/index.php(3) : runtime-created function on line 25

Warning: file_get_contents(/home/content/76/3891476/tmp/sess_cb7cacc48e9b5c7244790bb572) [function.file-get-contents]: failed to open stream: No such file or directory in /home/content/76/3891476/html/content/index.php(3) : runtime-created function on line 126
Natural Alternatives International, Inc. News http://www.nai-online.com/content en NPA President Mark Le Doux Highlights Accomplishments and Goals for Association in Letter to Members Legislative Victories, Membership and Cash Flow all on the Rise in First Half of 2016 Mandatory Participation in TruLabel and New By-Laws Planned for 2016 http://www.nai-online.com/content/?q=node/61 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>WASHINGTON, D.C. – In an open letter to Natural Products Association members, Mark Le Doux, President of the association’s board of directors, highlighted accomplishments and laid out key initiatives for 2016. The letter is an update for the membership following a productive board of directors meeting at NPA’s new offices on Capitol Hill in Washington, DC on July 5, 2016. </p> <p>“Membership and revenue are up, and we have a lot of exciting plans for the association coming down the pipeline. Our grassroots and legislative efforts are paying off, as we’ve seen with the recent victory in Massachusetts and Puerto Rico,” said Dan Fabricant, Ph.D., CEO and Executive Director of NPA. </p> <p>“Our plans to strengthen NPA’s trusted TruLabel and make participation in the program a requirement for membership will further our goals of proving the natural products industry trustworthy, accountable and legitimate. Updating our by-laws for the first time since Lyndon Johnson was in office will modernize the way our association is governed,” said Dr. Fabricant.</p> <p>“The first half of 2016 has been a tremendous success for our organization, and we have our members and leadership team here in Washington to thank for that,” Dr. Fabricant concluded. “We are looking forward to closing out the year on just as high of a note as we started it.” </p> <p>Mr. Le Doux has served in his role as Acting President since February of 2016, succeeding Roxanne Green. “Mark is a valuable asset to NPA, and we’re happy to have him on the team in his leadership role,” added Dr. Fabricant. Le Doux is the CEO of Natural Alternatives International, Inc. (NAI), a Carlsbad, CA based formulator, manufacturer and marketer of nutritional supplements. He has been a member of NPA’s board of directors since 2010 and has also served as chairman of NPA’s ComPLI Committee. </p> <p>Highlights from the letter, which can be viewed in its entirety here, include: </p> <p>• Plans to make participation in NPA’s TruLabel program a mandatory part of NPA membership; </p> <p>• Positive cash flow and overall revenue increases for the first five months of 2016, largely thanks to increased membership and changes to membership dues that will enable the NPA to more actively pursue its goals; </p> <p>• NPA’s successful partnership with UL (Underwriters Laboratory) to offer third-party GMP certification; </p> <p>• Grassroots efforts to engage Members of Congress on both sides of the aisle and encouraging NPA member contact with them while they are home on recess;</p> <p>• The Natural Products Foundation’s letter-writing efforts to encourage investigations of questionable practices and products from the FDA and FTC; </p> <p>• NPA PAC’s efforts to engage lawmakers on Capitol Hill; </p> <p>• Legislative and regulatory updates including a recently passed GMO labeling bill that reduces the confusion of varied state laws regarding GMO labeling; </p> <p>• NPA’s submission of a 33-page FDA brief to explore the definition of “natural” and help clarify policies relating to natural products;</p> <p>• NPA’s success fighting a Massachusetts regulation that would have reduced athletes’ access to supplements; and</p> <p>• Grassroots efforts to eliminate onerous restrictions on dietary supplements in Puerto Rico as well as the intrusive regulations proposed under California’s Proposition 65. </p> <p>Natural Products Association<br /> The Natural Products Association (NPA) is the trade association representing the entire natural products industry. We advocate for our members who supply, manufacture and sell natural ingredients or products for consumers. The Natural Products Association promotes good manufacturing practices as part of the growth and success of the industry. Founded in 1936, NPA represents over 1,400 members accounting for more than 10,000 locations of retailers, manufacturers, wholesalers and distributors of natural products, including foods, dietary supplements, and health/beauty aids. Visit <a href="http://www.NPAinfo.org">www.NPAinfo.org</a>.<br /> Follow NPA on social media: </p> <p>• Facebook: Natural Products Association and The Natural Seal<br /> • Twitter: NPA National and NPA Natural Seal<br /> • LinkedIn: Natural Products Association, Natural Products Group and Grassroots Action Network</p> <p>Natural Products Association: 440 1st Street, NW, Ste. 520, Washington, DC, 20001</p> </div></div></div> Tue, 26 Jul 2016 20:00:00 +0000 Natural Alternatives International 61 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/61#comments Natural Alternatives International, Inc. Announces Expanded Commitment to the CarnoSyn® Brand and Previews SR CarnoSyn® Sustained Release Product Formulation http://www.nai-online.com/content/?q=node/60 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Oct. 7, 2015 -- Natural Alternatives International, Inc. (NAI) (NASDAQ: NAII), a global formulator and manufacturer of customized nutritional supplements, announced its expanded commitment to <a href="http://www.carnosyn.com/" target="_blank">CarnoSyn</a>®, a studied, patent-protected beta-alanine ingredient for supporting an increase in muscle carnosine and athletic performance. As part of its commitment, NAI began to directly oversee the sales and distribution of CarnoSyn® in the United States and abroad as of April 1st, 2015. NAI is showcasing CarnoSyn® and previewing SR CarnoSyn® - a new sustained release beta-alanine powder - at the upcoming <a href="http://west.supplysideshow.com/" target="_blank">SupplySide West</a> conference in Las Vegas, Nevada on October 5-9, 2015.</p> <p>NAI is a global manufacturer recognized for its strong commitment to health, scientific integrity and quality, which extends to its CarnoSyn® brand. CarnoSyn® is backed by 55 clinical studies which demonstrate the positive effects of CarnoSyn® and SR CarnoSyn® supplementation. The CarnoSyn® brand is protected by NAI's growing portfolio of 14 patents in the United States and 10 abroad, which guarantee quality and exclusivity for the brand. </p> <p>"NAI is investing significant resources towards building, promoting and protecting the CarnoSyn® brand, as well as supporting the upcoming launch of our new SR CarnoSyn® sustained release beta-alanine powder ," said Mark A. LeDoux, NAI's CEO and board chairman. "We're very excited to expand the CarnoSyn® portfolio of products and to work in partnership with both current and prospective partners to help drive business opportunities."</p> <p>CarnoSyn® beta-alanine is a leading ingredient in sports nutrition formulations, supporting the synthesis of muscle carnosine, which acts as a buffer, delaying the onset of muscle fatigue and failure. Supplementing with CarnoSyn® beta-alanine, which combines with histidine in the body to form carnosine, significantly increases the levels of carnosine in the muscle. Carnosine's ability to buffer hydrogen ions keeps muscles contracting longer, which extends endurance, speeds muscle recovery, builds muscle strength and enhances peak performance capabilities. </p> <p>SR CarnoSyn® beta-alanine provides formulation flexibility via a sustained release profile, extending the benefits of beta-alanine to a much broader group of consumers with active lifestyles. SR CarnoSyn® delivers higher levels of beta-alanine more comfortably in a single dose. SR CarnoSyn® results in a sustained beta-alanine release that stays in the body longer for carnosine synthesis. The net effect is higher muscle retention of carnosine. SR CarnoSyn® delivers much higher dosage levels than instant release CarnoSyn® before reaching the typical paresthesia-sensation threshold.</p> <p>In an effort to fortify the CarnoSyn® brand and deliver additional value to its customers, NAI has expanded its commitment to the following areas of development:</p> <ul><li>Continued Research and Development: NAI will continue to fund and support additional clinical studies to further strengthen substantiation, future product claims, and an expanded product line</li> <li>Robust B2B and B2C Marketing and Advertising Programs: NAI will commit substantial resources to help increase brand awareness and drive new business opportunities</li> <li>Vigorous Patent Protection: NAI will continue to dedicate resources to track and enforce compliance with its patent rights</li> <li>Inventory and Supply Control: NAI will continue to invest in robust inventory levels and supply chain support to guarantee material availability, ensure timely production and consistency in product safety and quality</li> </ul><p>NAI will exhibit in booth #1506 at SupplySide West, where it will preview a new sustained release powder delivery form, SR CarnoSyn®, which delivers higher levels of beta-alanine more comfortably in a single dose.<br /> NAI's CEO and Chairman of the Board, Mark LeDoux, will also participate in a panel of industry influencers to discuss safety, regulatory, and consumer confidence issues for the supplement industry, which takes place on October 7th from 9-11am. For more information, please visit <a href="http://west.supplysideshow.com/panel-discussions.asp" target="_blank">SupplySide Panel Discussions.</a></p> <p><strong>About Natural Alternatives International, Inc.</strong></p> <p>Natural Alternatives International, Inc. (NAI) is a leading formulator and manufacturer of customized nutritional supplements. The Company's comprehensive partnership approach to client servicing is unique within the industry, combining clinical research, science-based formulation, advanced quality assurance testing methodologies, superior manufacturing and packaging capabilities, and broad marketing experience to create nutritional products that are formulated to address specific health conditions. </p> <p>Founded in 1980, NAI prides itself on a strong commitment to health, scientific integrity and quality. It provides comprehensive solutions that include custom formulations based on scientific research, the highest manufacturing standards, supervision of international regulatory compliance, and marketing support. It has established partnerships and works to develop tailored solutions for its clients' nutritional product needs. With state-of-the-art manufacturing facilities in Vista, California and Lugano, Switzerland, and a sales presence in Yokohama, Japan, NAI is able to fulfill the needs of its customers around the world.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers that these statements involve risks and uncertainties, that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a></p> </div></div></div> Wed, 07 Oct 2015 16:25:00 +0000 Natural Alternatives International 60 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/60#comments Natural Alternatives International, Inc. Promotes President and Chief Financial Officer http://www.nai-online.com/content/?q=node/59 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Oct. 1, 2015, Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced the promotions of Kenneth Wolf to President and Michael Fortin to Chief Financial Officer.</p> <p>Mr. Wolf has been the Chief Financial Officer and the Treasurer of the Company since February 2008, Secretary of the Company since February 2009 and Chief Operating Officer since June 2010. Prior to joining NAI, Mr. Wolf held senior financial and managerial positions over the last 25 years primarily with public reporting companies in the consumer goods industry. Mr. Wolf received his Certified Public Accountant license from the State of California and a Bachelor of Science in Business Administration – Accounting from Fresno State University, California.</p> <p>Mr. Fortin has been NAI's Director of Accounting and SEC Reporting since April 2008. Before joining NAI, Mr. Fortin was the Director of Finance for K2 Licensed Products, a subsidiary of Jarden Corporation, a consumer products company specializing in licensed sporting goods, Manager – Financial Accounting Operations for HSBC Auto Finance, a subsidiary of HSBC Bank USA, and an audit senior for Arthur Andersen LLP and KPMG LLP. Mr. Fortin received his Certified Public Accountant license from the State of California and a Bachelor of Science in Business Administration – Accounting from San Diego State University, California.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "Both gentlemen have served NAI with distinction for years, and always exemplified the highest professional standards in all of their work at NAI. I am pleased to welcome them to their newly expanded roles. Dedication to excellence, drive to exceed customer expectations, commitment to world class standards of quality and transparency, and a mature capacity to grasp strategic opportunities are all qualities that are needed in any successful manufacturing entity, especially one with such an international footprint as NAI. As I continue in my position as CEO and Chairman, having Ken and Mike in their expanded roles will allow me to focus more on the critical work of fostering international expansion of our enterprise as well as working to enhance global consumer confidence with essential strategic regulatory initiatives."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to management performance, and our future financial and operating results. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.</p> <p>CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a></p> </div></div></div> Thu, 01 Oct 2015 19:15:00 +0000 Natural Alternatives International 59 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/59#comments Natural Alternatives International, Inc. Files Unfair Competition, False Advertising and Disparagement Complaint Against Creative Compounds Inc. http://www.nai-online.com/content/?q=node/58 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that it has filed a Complaint against Creative Compounds Inc. ("Creative") to stop Creative from intentionally and improperly trying to mislead NAI's actual and potential customers and wrongfully interfering with NAI's CarnoSyn® beta-alanine business. The suit was filed in U.S. District Court for the Southern District of California.</p> <p>NAI sells beta-alanine to customers under the trademark CarnoSyn®. NAI also owns a robust portfolio of 34 patents in the United States and foreign countries (14 in the United States) related to beta-alanine. In numerous scientific studies, CarnoSyn® beta-alanine, when used as a dietary supplement, has been proven to delay the onset of fatigue in muscle cells, thereby eliminating muscle fatigue and soreness and has been shown to improve athletic performance.</p> <p>The Complaint alleges that, on or about September 5, 2015, Creative, which sells generic beta-alanine, sent an internet communication to customers and potential customers of beta-alanine making numerous false and misleading statements regarding Creative's own generic beta-alanine, NAI, CarnoSyn® beta-alanine, and NAI's intellectual property rights. Creative, according to the Complaint, engaged in unfair competition, false advertising, trade libel and product disparagement, and intentional interference with NAI's business – all designed to improperly boost its sales and intentionally interfere with NAI's expanding CarnoSyn® business.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI filed this action to stop Creative from intentionally and improperly trying to mislead NAI's current and potential customers and wrongfully interfering with NAI's CarnoSyn® beta-alanine business." He went on to say that "NAI has invested significant time and money to build, promote and expand this business and we will pursue all appropriate legal avenues to protect our CarnoSyn® beta-alanine brand and intellectual property rights."</p> <p>NAI previously sued DNP International Co., Inc., a generic beta-alanine supplier, for unfair competition and related claims. As a result of the suit, DNP and its affiliates exited the beta-alanine business.</p> <p>NAI is represented by Kevin M. Bell and Richard J. Oparil of Porzio, Bromberg &amp; Newman, P.C.</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a></p> </div></div></div> Fri, 18 Sep 2015 22:00:00 +0000 Natural Alternatives International 58 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/58#comments Natural Alternatives International, Inc. Announces Fiscal 2015 Results http://www.nai-online.com/content/?q=node/57 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $3.3 million, or $0.49 per diluted share, on net sales of $79.5 million for the fiscal year ended June 30, 2015. </p> <p>Fiscal 2015 net sales from contract manufacturing activities increased $2.3 million or 3.5% as compared to the prior fiscal year due primarily to higher sales volumes of existing products in existing markets and new product sales to new customers. CarnoSyn® beta-alanine royalty and licensing revenue increased 67.9% to $9.1 million during fiscal 2015 as compared to $5.4 million for fiscal 2014. The increase in CarnoSyn® beta-alanine revenue was primarily due to the increase in raw material sales as a result of taking over the direct sale and distribution of CarnoSyn® beta-alanine effective April 1, 2015. Net sales from our branded products declined 39.8% to $698,000 in fiscal 2015 as compared to fiscal 2014 due to the discontinuation of this product line effective December 31, 2014.</p> <p>Net income for fiscal 2015 was $3.3 million, or $0.49 per diluted share, as compared to net income of $2.0 million for fiscal 2014, or $0.29 per diluted share.</p> <p>Net sales for the fourth quarter ended June 30, 2015 increased 6.6% to $22.6 million as compared to $21.2 million for the prior year period. The increase in net sales during the fourth quarter was primarily related to increased beta-alanine raw material sales. Net income in the fourth quarter of fiscal 2015 was $1.0 million or $0.15 per diluted share, as compared to net income of $1.1 million or $0.16 per diluted share in the fourth quarter of fiscal 2014.</p> <p>As of June 30, 2015, NAI had cash and cash equivalents of $18.6 million and working capital of $34.5 million compared to $19.5 million and $31.3 million, respectively, as of June 30, 2014. As of June 30, 2015, we had no debt outstanding and $5.5 million available under our working capital lines of credit.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer, stated, "Excellent teamwork and execution across the business units contributed to growth in revenues and earnings for our shareholders. Our continued emphasis on quality and our commitment to maintaining and expanding our multiple independent quality certifications has generated increased confidence from our clients, and we are excited about the opportunities before us to expand our footprint around the globe. </p> <p>"The work that we continue to do in research with CarnoSyn® beta-alanine is generating widespread support in the research community, and that is translating into growing sales opportunities in varied domestic and international market channels. We are completing an expansion of our facilities in Switzerland to accommodate burgeoning demand, and have taken steps in our North American operations to upgrade and streamline our processes with an eye to greater efficiencies and improved return on investment."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a></p> </div></div></div> Fri, 18 Sep 2015 20:00:00 +0000 Natural Alternatives International 57 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/57#comments Natural Alternatives International, Inc. Announces Fiscal 2015 Q3 Results http://www.nai-online.com/content/?q=node/56 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $788,000 or $0.12 per diluted share on net sales of $19.6 million for the quarter ended March 31, 2015.</p> <p>Net sales for the three months ended March 31, 2015 increased $500,000 or 2.5% from $19.1 million recorded in the comparable prior year period. For the quarter ended March 31, 2015, contract manufacturing sales decreased $400,000 or 2.1% from the comparable quarter last year due primarily to lower sales of established products to existing customers partially offset by new product sales to new customers. Patent and trademark licensing revenue increased 100.7% to $2.3 million during the quarter ended March 31, 2015 as compared to the prior year period.</p> <p>Net sales for the nine months ended March 31, 2015 increased 7.9% to $56.9 million from $52.8 million recorded in the comparable prior year period. Contract manufacturing sales during the first nine months of fiscal 2015 increased $3.5 million or 7.2% from the comparable prior year period and patent and trademark licensing revenue increased $900,000 or 23.5% during this same period. We discontinued our Pathway to Healing® branded product line and all termination activities were substantially completed in the prior quarter. As a result our branded products sales decreased $191,000 or 21.5% for the first nine months of fiscal 2015.</p> <p>Net income for the first nine months of fiscal 2015 totaled $2.4 million or $0.35 per diluted share compared to net income of $904,000 or $0.13 per diluted share in the comparable prior year period. The increase in net income was primarily attributable to higher contract manufacturing sales, increased licensing revenue, along with a decrease in patent prosecution expenses and a 1.9% gross margin improvement related to a favorable product sales mix. Patent litigation and prosecution expenses totaled $1.1 million for the first nine months of fiscal 2015 as compared to $1.7 million for the comparable prior year period.</p> <p>In an effort to increase our top-line revenue and profit profile, and to take advantage of various strategic opportunities, including possible additional contract manufacturing services, we elected not to renew our CarnoSyn® license agreement with Compound Solutions Inc. which expired on March 31, 2015. Effective April 1, 2015, we began selling CarnoSyn® beta-alanine raw material and directly licensing our related patent and trademark rights.</p> <p>In March 2015, NAI attained certification by Natural Food Certifiers (NFC) as an Organic Processor and Handler under the USDA National Organic Program Standards. NAI adds Organic Certification to its list of regulatory and compliance registrations including NSF International GMP certification, NSF "GMP for Sport" certification, Therapeutic Goods Administration (TGA) GMP certification, Health Canada GMP clearance, and Kosher and Halal certifications. We are pleased to secure another level of quality assurance for our clients in the organic market.</p> <p>As of March 31, 2015, we had cash of $19.4 million and working capital of $34.7 million compared to $19.5 million and $31.3 million, respectively, as of June 30, 2014. As of March 31, 2015, we had $5.5 million available under our line of credit agreements with no amount outstanding.</p> <p>Mark A. Le Doux, Chairman and Chief Executive Officer stated, "The third quarter ended March 31, 2015 has been a challenging time with foreign currency rate declines, commercial port congestion, and quality questions being raised about certain products and other companies by various government officials in the USA. Given these business headwinds, we are pleased with our third quarter results, and we remain cautious about the future impact of these challenges and other uncertainties related to the current business environment. As we move forward with the direct distribution of CarnoSyn® beta-alanine, we expect to garner new clients and new product applications through expanded investment in marketing, advertising and new product development efforts. We also remain hopeful we may have resolution to the ongoing litigation associated with our patent portfolio surrounding CarnoSyn® beta-alanine.</p> <p>"Our steadfast commitment to quality remains the driving force of our dedicated global team members, and we are ever mindful of the mission to exceed our customers' expectations while bringing the best of health to the world based on sound science and longstanding integrity."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to expand our contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Tue, 12 May 2015 20:00:00 +0000 Natural Alternatives International 56 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/56#comments Natural Alternatives International, Inc. Announces Fiscal 2015 Q2 Results http://www.nai-online.com/content/?q=node/55 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.1 million or $0.16 per diluted share on net sales of $18.6 million for the quarter ended December 31, 2014.</p> <p>Net sales during the three months ended December 31, 2014 increased $2.1 million or 13.0% from $16.5 million recorded in the comparable prior year period. For the quarter ended December 31, 2014, private label contract manufacturing sales increased $1.7 million or 11.2% from the comparable quarter last year due primarily to higher sales of existing products and new customer product sales. Patent and trademark licensing revenue increased 26.5% to $1.5 million during the second quarter of fiscal 2015 as compared to $1.2 million for the comparable prior year period. This increase related primarily to the timing of current year shipments to various customers as compared to the prior year period. Our branded products sales totaled $428,000 for the second quarter of fiscal 2015 as compared to $278,000 for the comparable prior year period. As previously reported, we elected to discontinue our Pathway to Healing® branded product line and all termination activities were substantially completed as of December 31, 2014.</p> <p>Net sales for the six months ended December 31, 2014 increased 11.0% to $37.3 million from $33.6 million recorded in the comparable prior year period. Contract manufacturing sales during the first six months of fiscal 2015 increased $3.8 million or 12.6% from the comparable prior year period and patent and trademark licensing revenue decreased $252,000 or 9.4% during this same period. Our branded products sales increased $102,000 or 17.1% for the first six months of fiscal 2015.</p> <p>Net income for the first six months of fiscal 2015 totaled $1.6 million or $0.23 per diluted share compared to net income of $282,000 or $0.04 per diluted share in the comparable prior year period. The increase in net income was primarily attributable to increased customer demand and a favorable international sales mix along with higher average EUR exchange rates which included the benefit of our currency hedging program. Our Patent litigation and prosecution expenses also declined to $524,000 for the first six months of fiscal 2015 as compared to $1.3 million for the comparable prior year period.</p> <p>As of December 31, 2014, NAI had cash of $20.1 million and working capital of $33.9 million compared to $19.5 million and $31.3 million, respectively, as of June 30, 2014. As of December 31, 2014, we had $5.5 million available under our line of credit agreements.</p> <p>Mark A. Le Doux, Chairman and Chief Executive Officer stated, "The results for this quarter are superior to the year earlier largely due to a favorable mix of product sales during the first half of fiscal 2015. While management is pleased with the operating results in the first half of the year, and especially in the quarter just ended, we anticipate risks during the second half of our fiscal year associated with changing sales patterns initiated by our customers, currency translation challenges, conflicted consumer perceptions brought on by recent regulatory actions involving several mass market retailers and their suppliers, and ongoing efforts to further manage our CarnoSyn® licensing and sublicensing activities. We continue to invest in keeping our facilities state of the art on both continents, and providing our customers with the levels of quality assurance unsurpassed in the industry."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to: our future financial and operating results, revenue, profits and financial condition, our ability to expand our contract manufacturing business, contain our fixed costs, expand our market presence, protect our intellectual property and manage the costs thereof, our ability to execute our business plan, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Thu, 12 Feb 2015 20:00:00 +0000 Natural Alternatives International 55 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/55#comments Natural Alternatives International, Inc. Announces Fiscal 2015 Q1 Results http://www.nai-online.com/content/?q=node/54 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $487,000 or $0.07 per diluted share on net sales of $18.7 million for the quarter ended September 30, 2014.</p> <p>Net sales during the three months ended September 30, 2014 increased $1.5 million or 9.0% from $17.2 million recorded in the comparable prior year period. For the quarter ended September 30, 2014, private label contract manufacturing sales increased $2.1 million or 14.0% from the comparable quarter last year due primarily to higher sales of existing products and new customer product sales. Patent and trademark licensing revenue decreased 36.7% to $961,000 during the first quarter of fiscal 2015 as compared to $1.5 million for the comparable prior year period. This decrease related primarily to the timing of current year shipments to various customers as compared to the prior year period, and the cessation of the Abbott beta-alanine licensing program during fiscal 2014. Our branded products sales totaled $269,000 for the first quarter of fiscal 2015 as compared to $317,000 for the comparable prior year period.</p> <p>Our revenue concentration risk for our two largest customers decreased to 57% as a percentage of our total private label contract manufacturing sales for the first three months of fiscal 2015 compared to 58% in the first three months of fiscal 2014.</p> <p>Net income in the first quarter of fiscal 2015 was $487,000 or $0.07 per diluted share compared to net income of $88,000 or $0.01 per diluted share in the first quarter of fiscal 2014. This increase was primarily attributable to increased private label contract manufacturing sales and a $658,000 reduction in beta-alanine litigation and patent compliance expense. These increases were partially offset by reduced patent and trademark licensing revenue and increased sales, marketing and employee compensation expenses.</p> <p>As of September 30, 2014, NAI had cash of $16.4 million and working capital of $32.9 million compared to $19.5 million and $31.3 million, respectively, as of June 30, 2014. As of September 30, 2014, we had $5.5 million available under our line of credit agreements.</p> <p>Mark A. Le Doux, Chairman and Chief Executive Officer stated, "The results for this quarter are superior to year earlier numbers, largely due to retained focus on core domestic and international sales, reduced expenditures in patent litigation, and continued investment in process improvements and new customer acquisition. Additionally, we are currently expanding our SwissMedic licensed facilities in Switzerland to meet anticipated growth in demand from current and prospective customers. Sales for CarnoSyn® have been accelerating during the current quarter and are anticipated to be consistent with historical norms for the balance of this fiscal year. We continue to see increasing acceptance of this remarkable compound in a variety of product offerings and are working to expand its application in multiple areas." </p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to: our future financial and operating results, revenue, profits and financial condition, our ability to expand our contract manufacturing business, contain our fixed costs, expand our market presence, protect our intellectual property and manage the costs thereof, our ability to execute our business plan, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Wed, 12 Nov 2014 20:00:00 +0000 Natural Alternatives International 54 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/54#comments Natural Alternatives International, Inc. Announces Fiscal 2014 Results http://www.nai-online.com/content/?q=node/53 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.0 million, or $0.29 per diluted share, on net sales of $73.9 million for the fiscal year ended June 30, 2014. </p> <p>Fiscal 2014 net sales from contract manufacturing activities increased $10.7 million or 18.8% as compared to the prior fiscal year due primarily to higher sales volumes of existing products in existing markets and new product sales to new customers. These increases were partially offset by lower average sales prices for a portion of our higher volume products and lower average EUR exchange rates. Royalty and licensing income related to license agreements for the use of our CarnoSyn® beta-alanine related patents and trademarks increased 13.4% to $5.4 million during fiscal 2014 as compared to $4.8 million for fiscal 2013. Net sales from our branded products declined 12.6% to $1.2 million during fiscal 2014 as compared to $1.3 million in the prior fiscal year.</p> <p>We have historically developed, manufactured and marketed our own branded products under the Pathway to Healing® product line. Due to the steady decline in sales of this product line over the past several years we elected to discontinue this business during the fourth quarter of fiscal 2014. This decision resulted in an inventory write-down charge totaling $320,000 which was included in our fourth quarter operating results. We anticipate that all termination activities related to the cessation of our branded business will be completed by the end of our second quarter of fiscal 2015. </p> <p>Net income for fiscal 2014 was $2.0 million, or $0.29 per diluted share, as compared to net income of $1.6 million for fiscal 2013, or $0.23 per diluted share.</p> <p>Net sales for the fourth quarter ended June 30, 2014 increased to $21.2 million or 26% as compared to $16.8 million for the prior year period. The increase in net sales during the fourth quarter was primarily related to higher sales volumes of existing products in existing markets and new product sales to new customers. Net income in the fourth quarter of fiscal 2014 was $1.1 million or $0.16 per diluted share, as compared to net income of $593,000 or $0.09 per diluted share in the fourth quarter of fiscal 2013.</p> <p>As of June 30, 2014, NAI had cash and cash equivalents of $19.5 million and working capital of $31.3 million compared to $16.7 million and $29.4 million, respectively, as of June 30, 2013. As of June 30, 2014, we had no debt outstanding and $5.6 million available under our working capital lines of credit.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer, stated, "We continue to focus on product integrity and quality, and to invest in our capacity to produce such products in the U.S. and abroad. We remain steadfast in our commitment to clients who are unwilling to forsake product integrity for short term savings. We also continue to support appropriate enforcement by regulatory agencies worldwide to help rid the industry of poor manufacturing processes and fraudulent mislabeling.</p> <p>"In the year ahead we will extend our active participation in the efforts of industry responsible organizations such as the Council for Responsible Nutrition and the Natural Products Association to influence various worldwide regulators including those involved with the Codex Alimentarius Commission and their efforts to improve international standards and allow for greater access to properly made nutritional supplements."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a></p> </div></div></div> Thu, 25 Sep 2014 20:00:00 +0000 Natural Alternatives International 53 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/53#comments DNP International Co., Inc. Agrees To Immediately Exit The Beta-Alanine Business As Part Of A Settlement With Natural Alternatives International, Inc. http://www.nai-online.com/content/?q=node/52 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that it has settled its unfair competition and patent infringement claims against DNP International Co., Inc. in U.S. District Court for the District of Delaware. As a result of the settlement, DNP will immediately end its involvement in business related to beta-alanine, or any salt, ester, amide or derivative of beta-alanine. DNP and its officers, directors, agents, employees, shareholders, and affiliates, including DNP's President David Ji, have agreed not to import, export, supply, make, use, distribute, offer for sale or sell beta-alanine.</p> <p>In the Delaware lawsuit, NAI alleged that DNP infringed U.S. Patent No. 8,067,381 ("the '381 patent"), entitled "Methods and compositions for increasing the anaerobic working capacity in tissues." The '381 patent, issued by the U.S. Patent and Trademark Office on November 29, 2011, is part of NAI's worldwide portfolio covering CarnoSyn® beta-alanine. NAI alleged that DNP supplied Chinese beta-alanine to nutritional supplement contract manufacturers, formulators and distributors in the United States. In a separate case brought in Delaware, NAI and its co-plaintiff, Compound Solutions, Inc. ("CSI"), alleged that DNP engaged in false advertising and unfair competition based on statements DNP made to the beta-alanine market in 2011. CSI is NAI's licensed distributor of CarnoSyn® beta-alanine in the United States. On July 29, 2014, the District Court signed an Order confirming dismissal of the cases.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI is pleased that this dispute against DNP has been resolved. By its agreement to immediately exit from the beta-alanine business, DNP has self-enjoined from infringing the '381 patent and other valid NAI patents. In a document filed with the Court, DNP also agreed that the '381 patent has not been found invalid by any final decision of a court or the Patent and Trademark Office." LeDoux went on to say that "NAI will continue to protect and defend its valuable beta-alanine intellectual property portfolio."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>. For more information about CarnoSyn® beta-alanine, see <a href="http://www.carnosyn.com">http://www.carnosyn.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Wed, 30 Jul 2014 20:00:00 +0000 Natural Alternatives International 52 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/52#comments Natural Alternatives International, Inc. Announces Dismissal of All Product Liability Suits Involving CarnoSyn® Beta-Alanine http://www.nai-online.com/content/?q=node/51 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Natural Alternatives International, Inc. (NAI) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the plaintiffs in four product liability suits have dismissed all of their claims against NAI relating to CarnoSyn® beta-alanine.</p> <p>NAI had been named as a co-defendant in cases involving a dietary supplement called Jack3d, which contains 1,3-dimethylylamylamine (also known as DMAA), which was formulated, made for and sold by USPLABS, LLC (USP). One of the ingredients used in the product was CarnoSyn® beta-alanine. NAI did not manufacture, formulate, package, distribute or sell the CarnoSyn® beta-alanine used by USP. NAI merely licensed the patents and trademark covering CarnoSyn® beta-alanine to USP.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "the product liability claims filed against the company were frivolous. There was absolutely no factual support for any suggestion that using beta-alanine as a dietary supplement, when taken as directed, was unsafe." LeDoux went on to say that "NAI's position has been completely vindicated. All of the claims against NAI were voluntarily dismissed by the plaintiffs, with prejudice, and without any payment by NAI. The benefits of using beta-alanine as a dietary supplement have been researched in over 20 peer reviewed scientific studies."</p> <p>The four dismissed cases are: Sparling, et al. v. Doyle, et al., U.S. District Court for the Western District of Texas, No. 13-cv-323; Carolyne, et al. v. USPLABS, LLC, et al., Superior Court for Los Angeles County, California, No. BC 508212; Little, et al. v. USPLABS, LLC, et al., Superior Court for Los Angeles County, California, No. BC 508212; and Reed, et al. v. USPLABS, LLC, et al., U.S. District Court for the Southern District of California, No. 13-cv-3135. Claims against NAI in a fifth case, Ogbonna v. USPLABS, LLC, et al., U.S. District Court for the Western District of Texas, No. 13-cv-347, were previously dismissed by the Court.</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Thu, 03 Jul 2014 20:00:00 +0000 Natural Alternatives International 51 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/51#comments Natural Alternatives International, Inc. Announces Fiscal 2014 Q3 Results http://www.nai-online.com/content/?q=node/50 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., May 13, 2014 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $622,000 or $0.09 per diluted share on net sales of $19.1 million for the quarter ended March 31, 2014.</p> <p>Net sales for the three months ended March 31, 2014 increased by $3.3 million or 20.8% from $15.8 million recorded in the comparable prior year period. For the quarter ended March 31, 2014, contract manufacturing sales increased $3.2 million or 22.0% from the comparable quarter last year due primarily to higher sales of established products to existing customers and new product sales to new customers. Patent and trademark licensing revenue increased 13.1% to $1.1 million during the quarter ended March 31, 2014 as compared to the prior year period. Our branded products sales totaled $294,000 for the third quarter of fiscal 2014 as compared to $321,000 for the comparable prior year period."</p> <p>Net sales for the nine months ended March 31, 2014 increased 14.7% to $52.8 million from<br /> $46.0 million recorded in the comparable prior year period. Contract manufacturing sales during the first nine months of fiscal 2014 increased $6.3 million or 15.0% from the comparable prior year period and patent and trademark licensing revenue increased $605,000 or 18.9% during this same period. Our branded products sales decreased $112,000 or 11.2% for the first nine months of fiscal 2014.</p> <p>Net income for the first nine months of fiscal 2014 totaled $904,000 or $0.13 per diluted share compared to net income of $977,000 or $0.14 per diluted share in the comparable prior year period. The decline in net income was primarily attributable to lower average sales prices for a portion of our higher volume products, an unfavorable international sales mix and lower average EUR exchange rates. Patent litigation and prosecution expenses totaled $1.7 million for the first nine months of fiscal 2014 as compared to $1.8 million for the comparable prior year period.</p> <p>As of March 31, 2014, we had cash of $15.2 million and working capital of $30.5 million compared to $16.7 million and $29.4 million, respectively, as of June 30, 2013. As of March 31, 2014, we had $5.6 million available under our line of credit agreements with no amount outstanding.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer remarked, “The third quarter ending March 31, 2014 demonstrated growth in sales and profitability over the prior period, yielding an increase of over $3 million in revenues and a tripling of profitability. This growth materialized from a variety of venues, particularly from contract manufacturing requirements for Asia, Europe and North America. With higher capacity utilization, NAI experienced greater efficiencies in throughput and overhead absorption, and continues to see growth potential in the future in a variety of markets.</p> <p>“In the last several months we have seen two seminal studies published in peer-reviewed journals extolling the virtues and benefits from the ingestion of our CarnoSyn® and sustained release SR CarnoSyn® beta-alanine ingredient. We continue to seek additional growth opportunities from clinical research surrounding beta-alanine and remain confident the validity and enforceability of our beta-alanine patents will be judicially upheld in the not too distant future.” </p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to expand our contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p> CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com"> investor@nai-online.com</a>.</p> <p><a href="../content/files/2014-05-13 NAI Press Release Q3 FY14 Earnings.pdf"><img src="../images/icpdf.gif" border="0" /></a> <a href="../content/files/2014-05-13 NAI Press Release Q3 FY14 Earnings.pdf">Printable version</a> (PDF, 32KB) | <a href="../content/files/NAI Consolidated Statements of Income.pdf"><img src="../images/icpdf.gif" border="0" /></a> <a href="../content/files/NAI Consolidated Statements of Income.pdf">Consolidated Statements of Income</a> (PDF, 8KB)</p> </div></div></div> Tue, 13 May 2014 19:30:00 +0000 Natural Alternatives International 50 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/50#comments Natural Alternatives International, Inc. Announces New Vice President Global Sales http://www.nai-online.com/content/?q=node/49 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., March 27, 2014 -- Natural Alternatives International, Inc. (NAI) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today the addition of Eugene M. Quast to lead its sales function as Vice President Global Sales.</p> <p>Mr. Quast's background spans over 30 years in the food and nutritional industries, with experience ranging from stick packs to ready-to-drink products, whey products and effervescent vitamins. Mr. Quast holds a BS from the University of Minnesota and is working towards his Masters in Business Administration from the University of Dubuque.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, stated, "Gene's vast sales experience demonstrates his ability to create effective sales teams and deliver on his sales growth strategies. I believe Gene will provide strong sales leadership for both our domestic and international sales teams and I look forward to working with Gene in creating and implementing new growth strategies for NAI in the years ahead."</p> <p>Mr. Quast added, "I am excited to be joining NAI and look forward to working with the entire team to grow and exceed all customer and stakeholder expectations for this great company."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to growth in sales, effective sales teams, and their impact upon our future financial and operating results. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Thu, 27 Mar 2014 19:30:00 +0000 Natural Alternatives International 49 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/49#comments Natural Alternatives International, Inc. Announces Fiscal 2014 Q2 Results http://www.nai-online.com/content/?q=node/48 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Feb. 12, 2014 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $194,000 or $0.03 per diluted share on net sales of $16.5 million for the quarter ended December 31, 2013.</p> <p>Net sales for the three months ended December 31, 2013 increased by $2.8 million or 20.4% from $13.7 million recorded in the comparable prior year period. For the quarter ended December 31, 2013, contract manufacturing sales increased $2.5 million or 20.1% from the comparable quarter last year due primarily to higher sales of established products from existing costumers and new product sales from new customers. Patent and trademark licensing revenue increased 39.9% to $1.2 million during the quarter ended December 31, 2013 as compared to the prior year period. Our branded products sales totaled $278,000 for the second quarter of fiscal 2014 as compared to $338,000 for the comparable prior year period.</p> <p>Net sales for the six months ended December 31, 2013 increased 11.6% to $33.6 million from $30.1 million recorded in the comparable prior year period. Contract manufacturing sales during the first six months of fiscal 2014 increased $3.1 million or 11.4% from the comparable prior year period and patent and trademark licensing revenue increased $500,000 or 21.5% during this same period. Our branded products sales decreased $85,000 or 12.5% for the first six months of fiscal 2014.</p> <p>Net income for the first six months of fiscal 2014 totaled $282,000 or $0.04 per diluted share compared to net income of $799,000 or $0.12 per diluted share in the comparable prior year period. The decline in net income was primarily attributable to lower average sales prices for a portion of our higher volume products, an unfavorable international sales mix and lower average EUR exchange rates. Patent litigation and prosecution expenses totaled $1.3 million for the first six months of fiscal 2014 as compared to $1.4 million for the comparable prior year period.</p> <p>As of December 31, 2013, we had cash of $16.4 million and working capital of $29.2 million compared to $16.7 million and $29.4 million, respectively, as of June 30, 2013. As of December 31, 2013, we had $5.6 million available under our line of credit agreements with no amount outstanding.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer commented, "As we exited our fiscal second quarter we realized an improvement in the sales order flow from several customers who completed their inventory reduction and product and packaging reconfiguration programs that we reported during the prior quarter. We continue to see significant growth in multiple Asian markets and continued business opportunities driven from what we believe is a growing trend to do business with companies like NAI with a positive regulatory reputation in the global markets.</p> <p>"New products have been launched and more are anticipated from our Swiss subsidiary in Europe, many of which take advantage of the 'approved health claims' we can help to deliver. With the Sochi Olympics under way, we are gratified to know that many of the participating Olympians have been training on our patented CarnoSyn® brand of beta-alanine. We also remain hopeful the litigation we have initiated against several infringers of our beta-alanine patents will conclude favorably in the not too distant future. We are optimistic as we enter the second half of our fiscal year that our financial performance should continue to improve."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to expand our contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Wed, 12 Feb 2014 20:30:00 +0000 Natural Alternatives International 48 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/48#comments Natural Alternatives International, Inc. Announces Fiscal 2014 Q1 Results http://www.nai-online.com/content/?q=node/47 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Nov. 13, 2013 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $88,000 or $0.01 per diluted share on net sales of $17.2 million for the quarter ended September 30, 2013.</p> <p>Net sales during the three months ended September 30, 2013 increased $700,000 or 4.2% from $16.5 million recorded in the comparable prior year period. For the quarter ended September 30, 2013, private label contract manufacturing sales increased $600,000 or 4.0% from the comparable quarter last year due primarily to higher sales of existing products and new customer product sales. This increase was partially offset by lower average sales prices for a portion of our higher volume products, an unfavorable sales mix and lower average EUR foreign exchange rates. Patent and trademark licensing revenue increased to $1.52 million or 10.5% during the first quarter of fiscal 2013 as compared to $1.37 million for the comparable prior year period. Our branded products sales totaled $317,000 for the first quarter of fiscal 2013 as compared to $342,000 for the comparable prior year period.</p> <p>Our revenue concentration risk for our two largest customers decreased to 58% as a percentage of our total private label contract manufacturing sales for the first three months of fiscal 2014 compared to 72% in the first three months of fiscal 2013.</p> <p>Net income in the first quarter of fiscal 2014 was $88,000 or $0.01 per diluted share compared to net income of $697,000 or $0.10 per diluted share in the first quarter of fiscal 2013. The decrease was primarily attributable to an unfavorable sales mix, lower average sales prices and lower average EUR foreign exchange rates.</p> <p>As of September 30, 2013, NAI had cash of $14.8 million and working capital of $29.5 million compared to $16.7 million and $29.4 million, respectively, as of June 30, 2013. As of September 30, 2013, we had $5.6 million available under our line of credit agreements.</p> <p>Mark A. Le Doux, Chairman and Chief Executive Officer noted, "There is no doubt that NAI management is disappointed with our profitability performance during this past quarter, however the customer driven activities that resulted in our profit shortfalls including inventory reductions, new packaging reconfigurations and shipment delays are expected to be completed during the present quarter. We have also added new clients who are experiencing successful launches in their target markets, and continue to see growth in certain parts of Europe as well as Asia. Several of our existing customers have also increased their order requirements from NAI to meet demand in markets such as Australia, Malaysia and South Korea. As a result, we believe our future operating results will improve as evidenced by our expanding open order backlog. We remain committed to executing on our business strategy and growing the business both domestically and internationally."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to: our future financial and operating results, revenue, profits and financial condition, our ability to expand our contract manufacturing business, contain our fixed costs, expand our market presence, protect our intellectual property and manage the costs thereof, our ability to execute our business plan, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.<br /> CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Wed, 13 Nov 2013 20:30:00 +0000 Natural Alternatives International 47 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/47#comments Natural Alternatives International, Inc. Announces Fiscal 2013 Results http://www.nai-online.com/content/?q=node/46 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Sept. 19, 2013 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.6 million, or $0.23 per diluted share, on net sales of $62.8 million for the fiscal year ended June 30, 2013. </p> <p>Fiscal 2013 net sales from contract manufacturing activities decreased $6.6 million as compared to the prior fiscal year due primarily to lower volumes of existing products in existing markets, lower average sales prices for a portion of our higher volume products and lower average EUR exchange rates. Royalty and licensing income related to license agreements for the use of our CarnoSyn® beta-alanine related patents and trademarks increased 2% to $4.7 million during fiscal 2013 as compared to $4.6 million for fiscal 2012, and raw material sales of beta-alanine totaled $103,000 during fiscal 2013 as compared to $3.4 million for fiscal 2012. </p> <p>During the second and third quarters of fiscal 2012, NAI purchased approximately $3.2 million of beta-alanine raw material to help ensure sufficient inventory to meet anticipated future customer demand. The majority of this raw material was sold or consumed during the third and fourth quarters of fiscal 2012. Due to the improvement in the worldwide supply of beta-alanine during late fiscal 2012, NAI discontinued its purchase and sale of beta-alanine raw materials during fiscal 2013. Net sales from our branded products declined $238,000 to $1.3 million during fiscal 2013 as compared to the prior fiscal year.</p> <p>The fiscal 2013 net sales decreases, coupled with higher per unit manufacturing costs associated with lower production levels, contributed to a $4.0 million decrease in income from operations during fiscal 2013 as compared to the prior fiscal year.<br /> Net income for fiscal 2013 was $1.6 million, or $0.23 per diluted share, as compared to net income of $4.2 million for fiscal 2012, or $0.59 per diluted share.</p> <p>Net sales for the fourth quarter ended June 30, 2013 decreased to $16.8 million as compared to $20.9 million for the prior year period. The decrease in net sales during the current quarter was primarily related to a $3.0 million of reduction in beta-alanine raw material sales and decreased contract manufacturing sales from existing customers, which was partially offset by a $708,000 increase in royalty and licensing income. Net income in the fourth quarter of fiscal 2013 was $593,000, or $0.09 per diluted share, as compared to net income of $777,000, or $0.11 per diluted share, in the fourth quarter of fiscal 2012. The decrease in net income on a quarter over quarter basis was attributable primarily to lower contract manufacturing sales and beta-alanine raw material sales.</p> <p>As of June 30, 2013, NAI had cash and cash equivalents of $16.7 million and working capital of $29.4 million compared to $14.5 million and $27.7 million, respectively, as of June 30, 2012. As of June 30, 2013, we had no debt outstanding and $5.5 million available under our working capital lines of credit.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer, stated, "During fiscal 2013 NAI experienced variable conditions in business activities that included customer driven inventory reductions, product pricing pressures and delayed new product launches. Even in the face of these headwinds, and our continued significant investment in prosecuting our growing patent estate, the fourth quarter demonstrated increases in patent and trademark royalty and licensing income through expanding acceptance of the usage of CarnoSyn® beta-alanine. While contract manufacturing sales were lower for a variety of reasons in the last fiscal year, we believe we remain poised to experience meaningful growth in both our top line sales and operating income for the entirety of fiscal 2014 primarily as a result of expanded demand from various existing and new customer relationships."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as the availability of beta-alanine, future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.<br /> CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a></p> </div></div></div> Thu, 19 Sep 2013 19:30:00 +0000 Natural Alternatives International 46 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/46#comments Natural Alternatives International, Inc. Sues Woodbolt, GNC and Bodybuilding.com for Patent Infringement http://www.nai-online.com/content/?q=node/45 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., June 17, 2013 -- Natural Alternatives International, Inc. (NAI) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that it has sued Woodbolt Distribution, LLC, also known as Cellucor (Woodbolt), GNC Corporation (GNC), and Bodybuilding.com, LLC (Bodybuilding.com) for patent infringement. The complaint, filed in U.S. District Court in Houston, Texas, alleges that Woodbolt's newly-introduced Neon Sport™ Volt™ product infringes two patents that are part of NAI's worldwide portfolio covering CarnoSyn® beta-alanine. NAI also asked the Court to preliminarily enjoin sales of Volt.</p> <p>NAI's complaint is based on two patents, U.S. Patent Nos. 8,067,381 ("the '381 patent") and 8,129,422 ("the '422 patent"), both entitled "Methods and compositions for increasing the anaerobic working capacity in tissues. "The complaint alleges that Woodbolt is marking the Neon Sport™ Volt™ product as "[a]n in your face, high energy pre-workout with unmatched doses of beta-alanine" and other ingredients, and that "Volt's signature ingredient is surely beta-alanine, and at max dose, Volt™ delivers, in many cases, more than 2x the amount of max dosed competing products."</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI's suit alleges that Woodbolt decided to launch a blatantly infringing beta-alanine product, Volt™, as a pre-workout supplement containing high amounts of beta-alanine. The suit also alleges infringement by GNC and BodyBuilding.com for marketing and distributing the infringing product. The defendants are well aware of NAI's '381 and '422 patents." He went on to say that "NAI will continue to take steps to protect and defend its valuable intellectual property portfolio."<br /> NAI previously sued Woodbolt in the Southern District of Texas for infringement of the '381 and '422 patents on other Woodbolt products – C4 Extreme, M5 Extreme, N0 Extreme, BCAA and Cre. That case is pending.</p> <p>NAI is represented in the case by the Patton Boggs LLP and Bracewell &amp; Guiliani law firms.<br /> NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Mon, 17 Jun 2013 22:38:00 +0000 Natural Alternatives International 45 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/45#comments Natural Alternatives International, Inc. Announces Fiscal 2013 Q3 and YTD Results http://www.nai-online.com/content/?q=node/43 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., May 14, 2013 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $178,000 or $0.03 per diluted share on net sales of $15.8 million for the quarter ended March 31, 2013.</p> <p>Net sales for the three months ended March 31, 2013 decreased $1.6 million or 9.1% from $17.4 million recorded in the comparable prior year period. For the quarter ended March 31, 2013, contract manufacturing sales decreased $438,000 or 2.9% from the comparable quarter last year due primarily to lower sales to existing customers, lower average sales prices for a portion of our higher volume products and lower average EUR exchange rates. Patent and trademark licensing revenue decreased 51.8% to $1.0 million during the quarter ended March 31, 2013 as compared to $2.1 million for the prior year period. This decrease resulted from lower patent licensing fee payments totaling $654,000 along with a reduction in beta-alanine raw material sales totaling $418,000. This licensing revenue was generated from our patent estate pursuant to license and supply agreements with third parties for the use and distribution of the ingredient known as beta-alanine sold under our CarnoSyn® trade name. Our branded products sales totaled $321,000 for the third quarter of fiscal 2013 as compared to $387,000 for the comparable prior year period.</p> <p>Net sales for the nine months ended March 31, 2013 decreased to $46.0 million or 11.5% from $51.9 million recorded in the comparable prior year period. Contract manufacturing sales during the first nine months of fiscal 2013 decreased $4.8 million or 10.3% from the comparable prior year period and patent and trademark licensing revenue decreased 22.7% or $939,000 during this same period. Our branded products sales decreased $191,000 or 16.0% for the first nine months of fiscal 2013.</p> <p>Net income for the first nine months of fiscal 2013 totaled $977,000 or $0.14 per diluted share compared to net income of $3.4 million or $0.48 per diluted share in the comparable prior year period. The decrease was primarily attributable to lower contract manufacturing sales and patent and trademark licensing revenue, increased raw material and manufacturing production costs, unfavorable foreign currency exchange rates and increased patent and prosecution expenses which totaled $1.8 million for the first nine months of fiscal 2013.</p> <p>As of March 31, 2013, we had cash of $14.6 million and working capital of $28.6 million compared to $14.5 million and $27.7 million, respectively, as of June 30, 2012. As of March 31, 2013, we had $5.5 million available under our line of credit agreements.</p> <p>"As anticipated, the quarter ended March 31, 2013 experienced various headwinds, but I am gratified we achieved a profit for the quarter in spite of these factors," noted Chairman and Chief Executive Officer Mark A. Le Doux. "As the Food and Drug Administration continues in its efforts to point out significant failings in compliance of the Good Manufacturing Practices with others in our industry, we continue to receive inquiries from a variety of potential customers who wish to protect their brand reputations by upgrading their supply chain relationships through a partnership with NAI.</p> <p>"During the current quarter we have begun to see traction building with certain client initiatives which we believe should result in increased orders in future periods. While we continue to support research in the uses for CarnoSyn® beta-alanine and at the same time actively pursue infringers, we are seeing continued growth in the adoption of CarnoSyn® beta-alanine in more and more product offerings."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, market acceptance and media attention towards our CarnoSyn® beta-alanine, our ability to expand our domestic and international contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Tue, 14 May 2013 20:30:00 +0000 Natural Alternatives International 43 at http://www.nai-online.com/content http://www.nai-online.com/content/?q=node/43#comments Natural Alternatives International, Inc. Announces Fiscal 2013 Q2 Results http://www.nai-online.com/content/?q=node/42 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Feb. 12, 2013 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $102,000 or $0.01 per diluted share on net sales of $13.7 million for the quarter ended December 31, 2012.</p> <p>Net sales for the three months ended December 31, 2012 decreased by $2.5 million or 15.3% from $16.2 million recorded in the comparable prior year period. For the quarter ended December 31, 2012, contract manufacturing sales decreased $2.5 million or 16.7% from the comparable quarter last year due primarily to lower sales of established products associated with lower consumer demand, delayed customer product launches and customer inventory reduction programs. Patent royalty and trademark licensing revenue increased 14.4% to $824,000 during the quarter ended December 31, 2012 as compared to the prior year period. Royalty and licensing revenue was derived through the sale and licensing of the ingredient known as beta-alanine sold under our CarnoSyn® trade name. Our branded products sales totaled $338,000 for the second quarter of fiscal 2013 as compared to $403,000 for the comparable prior year period.<br /> Net sales for the six months ended December 31, 2012 decreased 12.6% to $30.1 million from $34.5 million recorded in the comparable prior year period. Contract manufacturing sales during the first six months of fiscal 2013 decreased $4.4 million or 13.8% from the comparable prior year period and patent and trademark licensing revenue increased $144,000 or 7% during this same period. Our branded products sales decreased $124,000 or 15.4% for the first six months of fiscal 2013.<br /> Net income for the first six months of fiscal 2013 totaled $799,000 or $0.12 per diluted share compared to net income of $2.3 million or $0.33 per diluted share in the comparable prior year period. The decline in net income was primarily attributable to decreased contract manufacturing sales, increased raw material and manufacturing production costs, unfavorable foreign currency exchange rates and increased patent litigation and prosecution expenses which totaled $1.4 million for the first six months of fiscal 2013.<br /> As of December 31, 2012, we had cash of $17.0 million and working capital of $27.9 million compared to $14.5 million and $27.7 million, respectively, as of June 30, 2012. As of December 31, 2012, we had $5.5 million available under our line of credit agreements.<br /> Mark A. LeDoux, Chairman and Chief Executive Officer commented, "The quarter ending December 2012 was clearly disappointing in terms of revenue and profitability. The trend for the current period remains difficult as well given the uncertainty of the timing of sales associated with our current customers' new product launches and planned initial sales of new customer products."<br /> "We were however, very pleased to recently receive notice of a positive ruling by the Chief Judge of the Delaware Federal District Court, which granted NAI's motion to dismiss a declaratory judgment patent case filed against it in Delaware in favor of the action properly brought by NAI in Houston, TX. With this recent development, we believe we are well positioned to move forward with our allegations in the Texas case against a significant infringer of our beta-alanine patent estate."<br /> "On December 11, 2012 we received our newest patent in the USA related to sustained release CarnoSyn® beta-alanine, US Patent Number 8329207, and are happy to announce that we received a notice of allowance on December 13, 2012 that a second sustained release CarnoSyn® beta-alanine patent has been approved for issuance by the US Patent Office."<br /> NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.<br /> This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to expand our contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Tue, 12 Feb 2013 20:30:00 +0000 Natural Alternatives International 42 at http://www.nai-online.com/content Natural Alternatives International, Inc. Announces Fiscal 2013 Q1 Results http://www.nai-online.com/content/?q=node/41 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif. -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $697,000 or $0.10 per diluted share on net sales of $16.5 million for the quarter ended September 30, 2012.</p> <p>Net sales during the three months ended September 30, 2012 decreased $1.8 million or 10.3% from $18.3 million recorded in the comparable prior year period. For the quarter ended September 30, 2012, private label contract manufacturing sales decreased $1.9 million or 11.2% from the comparable quarter last year due primarily to lower sales to our two largest customers and unfavorable foreign currency exchange rates which generated lower average sales prices during the current year period. Patent and trademark licensing revenue increased to $1.4 million or 3.0% during the first quarter of fiscal 2013 as compared to $1.3 million for the comparable prior year period. Our branded products sales totaled $342,000 for the first quarter of fiscal 2013 as compared to $401,000 for the comparable prior year period.</p> <p>Our revenue concentration risk for our two largest customers decreased to 72% as a percentage of our total private label contract manufacturing sales for the first three months of fiscal 2013 compared to 77% in the first three months of fiscal 2012.</p> <p>Net income in the first quarter of fiscal 2013 was $697,000 or $0.10 per diluted share compared to net income of $1.5 million or $0.22 per diluted share in the first quarter of fiscal 2012. The decrease was primarily attributable to lower consolidated sales, increased manufacturing costs associated with lower units of production and increased legal expenses related to our beta-alanine patent estate.</p> <p>As of September 30, 2012, NAI had cash of $14.4 million and working capital of $28.6 million compared to $14.5 million and $27.7 million, respectively, as of June 30, 2012. As of September 30, 2012, we had $5.5 million available under our line of credit agreements.</p> <p>Mark A. Le Doux, Chairman and Chief Executive Officer, noted, "NAI continues to demonstrate leadership in dietary supplement research, intellectual property, and manufacturing of supplements. Recently the United States Patent Office has provided a notice of allowance for one of our latest patent applications in the field of timed-release beta-alanine. Timed-released beta-alanine is now available from Natural Alternatives International in the form of SR CarnoSyn® 800 milligram tablets. With research demonstrating the added value of this dosage form, we are actively promoting this remarkable product in various channels of commerce. In addition to this new patent allowance in the U.S., we have secured similar responses from patent agencies in Canada and South Korea. In addition, we have additional patent applications pending globally. While NAI experienced a reduction in contract manufacturing requirements from its clients in this quarter, we are seeing signs of additional opportunities on the horizon and are planning to generate additional revenues while expanding our client base globally." </p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to: our future financial and operating results, revenue, profits and financial condition, our ability to expand our contract manufacturing business, contain our fixed costs, expand our market presence, protect our intellectual property and manage the costs thereof, our ability to execute our business plan, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Wed, 14 Nov 2012 20:30:00 +0000 Natural Alternatives International 41 at http://www.nai-online.com/content Natural Alternatives International, Inc. Announces New Sustained Release Beta-Alanine Intellectual Property http://www.nai-online.com/content/?q=node/40 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif. -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance of its patent application directed to sustained release formulations of beta-alanine. This Notice follows the September 14, 2012, issuance of NAI's corresponding sustained release patent in Canada and a similar Notice of Allowance in South Korea. This new intellectual property becomes part of NAI's growing portfolio covering its CarnoSyn® beta-alanine and SR CarnoSyn® product.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI is very excited by the addition of this new intellectual property related to a broad range of sustained release formulations for beta-alanine compositions. We believe this new patented technology will dramatically expand the use of beta-alanine to a much broader group of consumers. These new patent rights will not expire until 2028, and further demonstrates our commitment and significant investment in the CarnoSyn® beta-alanine business." </p> <p>Dr. Roger Harris, a named inventor on NAI's new sustained release intellectual property, added, "The use of extended release formulations for beta-alanine is an advancement in supplement intake. The result is an increase in the beneficial amount of beta-alanine retained in the body while reducing loss through metabolic processes. Additionally, sustained release formulations minimize or reduce parasthesia, a common side effect that can be experienced by those taking beta-alanine as an individual amino acid." Using sustained release forms of beta-alanine will not only meet the needs of bodybuilders, but also expand into other areas of use by individuals.</p> <p>Since 2008, over 30 peer-reviewed studies have been published related to beta-alanine supplementation. Thirteen of these studies were directed to sustained release forms of beta-alanine, eight of which were published in 2012 alone.</p> <p>Initially, NAI intends to launch a sustained release beta-alanine product in tablet form. It will be exclusively manufactured by NAI at its facilities in Vista, CA and sold by its exclusively licensed distributor, Compound Solutions, Inc., ("CSI"), a science and marketing based distributor of raw materials to the sports nutrition, dietary supplement, food, pharmaceutical and personal care industries. NAI intends to expand its offering of various sustained release delivery systems into other forms such as pills, capsules, gel tabs, chewable tablets and powder. NAI also plans to work with companies to develop and manufacture customized formulations covered by its intellectual property.</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> <p>CONTACT – Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or <a href="mailto:investor@nai-online.com">investor@nai-online.com</a>.</p> </div></div></div> Tue, 06 Nov 2012 22:00:00 +0000 Natural Alternatives International 40 at http://www.nai-online.com/content Mark LeDoux To Speak at Supply Side West 2012, November 8, 2012 1:00 - 1:50PM http://www.nai-online.com/content/?q=node/39 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>TOPIC: Where Do We Go From Here? Understanding the Landscape for Dietary Supplements for 2013 and Beyond</p> <p>• Almost 600 inspections have taken place under the applicable GMP regulations (21 CFR 111), and over half of these have demonstrated basic violations. <br /><br /> • As FDA ratchets up its reviews beyond basics, what happens to companies in non-compliance? <br /><br /> • With DMAA and other items having made headlines in the past year, where does the plaintiff’s bar see opportunity in this industry? <br /><br /> • With the certain passage of the GMO labeling act referendum in California, what can industry expect from yet another bounty-hunter statute (like Proposition 65)? <br /><br /> • Almost 20 years since the passage of DSHEA, will Congress seek to amend this law in light of the huge non-compliance with the regulations governing manufacturing? <br /></p> <p><img src="../images/SSW12_exhibitor_logo.jpg" /></p> </div></div></div> Thu, 25 Oct 2012 21:18:08 +0000 Natural Alternatives International 39 at http://www.nai-online.com/content Natural Alternatives International, Inc. Announces Fiscal 2012 Results http://www.nai-online.com/content/?q=node/38 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>• 30% Increase in Net Sales over Fiscal 2011</p> <p>• 167% Increase in Income From Operations over Fiscal 2011</p> <p>SAN MARCOS, Calif., Sept. 21, 2012 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $4.2 million, or $0.59 per diluted share, on net sales of $72.8 million for the fiscal year ended June 30, 2012. The fiscal 2012 results represent a 30% growth in net sales and a 167% growth in income from operations as compared to fiscal 2011.</p> <p>Fiscal 2012 net sales from contract manufacturing activities increased $11.0 million as compared to the prior fiscal year due primarily to higher sale volumes generated from our existing customers, new product sales, and sales associated with new customer products. Royalty and licensing income related to license agreements for the use of our CarnoSyn® beta-alanine related patents and trademarks increased 164% to $4.6 million during fiscal 2012 as compared to $1.7 million for fiscal 2011, and raw material sales of beta-alanine totaled $3.4 million during fiscal 2012 as compared to zero for fiscal 2011. The increase in beta-alanine royalty and licensing income during the current fiscal year was primarily related to an expanded customer base and increased raw material sales. Net sales from our branded products declined $261,000 to $1.6 million during fiscal 2012 as compared to the prior fiscal year. </p> <p>The fiscal 2012 net sales increases, coupled with a 220 basis point gross margin improvement, contributed to a $3.9 million or 167% increase in income from operations during fiscal 2012 as compared to the prior fiscal year. </p> <p>Net income for fiscal 2012 was $4.2 million, or $0.59 per diluted share, as compared to net income of $5.1 million for fiscal 2011, or $0.71 per diluted share. Our fiscal 2012 net income results included an income tax provision of $2.1 million while our fiscal 2011 net income results included a net tax benefit of $2.7 million, or $0.38 per diluted share, associated with the reduction of a valuation allowance on our net deferred tax assets. </p> <p>Net sales for the fourth quarter ended June 30, 2012 increased to $20.9 million as compared to $14.4 million for the prior year period. The increase in net sales during the current quarter was primarily related to $3.0 million of beta-alanine raw material sales and increased contract manufacturing sales from new and existing customers. Net income in the fourth quarter of fiscal 2012 was $777,000, or $0.11 per diluted share, as compared to net income of $3.1 million, or $0.44 per diluted share, in the fourth quarter of fiscal 2011. The decrease in net income on a quarter over quarter basis was attributable primarily to the recognition of a $3.1 million tax benefit associated with the reduction in a valuation reserve on our net deferred tax assets during the fourth quarter of 2011, as compared to a $225,000 income tax provision recognized during the fourth quarter of 2012.</p> <p>As of June 30, 2012, NAI had cash and cash equivalents of $14.5 million and working capital of $27.7 million compared to $15.5 million and $22.9 million, respectively, as of June 30, 2011. As of June 30, 2012, we had no debt outstanding and $5.5 million available under our working capital lines of credit.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer, stated, "By staying focused on our core objectives, NAI experienced solid growth in both net sales and operating income during fiscal 2012. We continue to pursue the economic value expansion of our growing CarnoSyn® beta-alanine patent estate, while prosecuting those who elect to violate our patent portfolio for their own benefit. We are also evaluating opportunities for expansion of our business footprint through accretive acquisitions given our growing cash position."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as the availability of beta-alanine, future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.</p> </div></div></div> Fri, 21 Sep 2012 20:30:00 +0000 Natural Alternatives International 38 at http://www.nai-online.com/content Natural Alternatives International, Inc. Announces Fiscal 2012 Q3 and YTD Results http://www.nai-online.com/content/?q=node/37 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>-- Continued Increase in Net Sales and Income from Operations</p> <p>-- Posts 13th Consecutive Quarter of Profitability</p> <p>SAN MARCOS, Calif., May 14, 2012 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $1.1 million or $0.15 per diluted share on net sales of $17.4 million for the quarter ended March 31, 2012. These results included a full effective tax rate in the third quarter of fiscal 2012 as compared to a lower rate in the prior year period.</p> <p>Net sales for the three months ended March 31, 2012 increased $4.0 million or 30.3% from $13.4 million recorded in the comparable prior year period. For the quarter ended March 31, 2012, contract manufacturing sales increased $2.7 million or 22.2% from the comparable quarter last year due primarily to higher sales to existing customers. Patent and trademark licensing revenue increased 190.6% to $2.1 million during the quarter ended March 31, 2012 as compared to $720,000 for the prior year period. This licensing revenue was generated from our patent estate pursuant to license and supply agreements with third parties for the use and distribution of the ingredient known as beta-alanine sold under our CarnoSyn® trade name. These increases were partially offset by a decline in our branded products sales, which totaled $387,000 for the third quarter of fiscal 2012 as compared to $431,000 for the comparable prior year period. </p> <p>Net sales for the nine months ended March 31, 2012 increased to $51.9 million or 25.2% from $41.5 million recorded in the comparable prior year period. Contract manufacturing sales during the first nine months of fiscal 2012 increased $7.8 million or 20.2% from the comparable prior year period and patent and trademark licensing revenue increased 210.3% or $2.8 million during this same period. These increases were partially offset by a decline in our branded products sales, which totaled $1.2 million for the first nine months of fiscal 2012 as compared to $1.4 million for the comparable prior year period. </p> <p>Net income for the first nine months of fiscal 2012 totaled $3.4 million or $0.48 per diluted share compared to net income of $1.9 million or $0.27 per diluted share in the comparable prior year period. The increase was primarily attributable to increased contract manufacturing sales and patent and trademark licensing revenue partially offset by increased income tax expense. The company's effective rate for the nine month period ended March 31, 2012 was 35.5% as compared to 15.4% in the comparable prior year period. The increase in the current year effective tax rate is a result of the full utilization of our federal net operating loss carry-forward deduction during the first quarter of fiscal 2012. </p> <p>As of March 31, 2012, we had cash of $11.1 million and working capital of $27.0 million compared to $15.5 million and $22.9 million, respectively, as of June 30, 2011. As of March 31, 2012, we had $5.6 million available under our line of credit agreements.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer indicated, "We are gratified with the continued positive performance of the corporation. This quarter marked the thirteenth consecutive quarter of positive operational earnings, and our performance in a full tax environment in this fiscal year has been strong on a year over year comparison. I believe it remains clear that as more and more regulatory actions and warning letters are being initiated by the Federal Food and Drug Administration against companies not compliant with the basic tenets of the federal laws governing manufacturing of dietary supplements, NAI is in an enviable position to expand its domestic and international client relationships. Companies who have a high degree of respect for their brand value and equity are seeking supply partners who have an unswerving commitment to ethical business practices and uncompromising quality processes. We believe we remain poised to fill this essential role for strategic partners that wish to sleep well at night.</p> <p>With the world turning its attention on the spectacle of the London Summer Olympic Games, our CarnoSyn® patented beta-alanine should receive ever more positive attention by the media and the research community. We received yet another patent on the use of beta-alanine on March 6, 2012 and continue to receive positive feedback from around the globe."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, market acceptance and media attention towards our CarnoSyn® beta-alanine, our ability to expand our domestic and international contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Mon, 14 May 2012 20:00:00 +0000 Natural Alternatives International 37 at http://www.nai-online.com/content Natural Alternatives International, Inc. Announces Issuance of New U.S. Patent Covering CarnoSyn(R) Beta-alanine http://www.nai-online.com/content/?q=node/36 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., March 21, 2012 -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,129,422 entitled "Methods and compositions for increasing the anaerobic working capacity in tissues." The new patent becomes part of the portfolio covering NAI's CarnoSyn® beta-alanine product.</p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said, "The new patent enhances NAI's portfolio by continuing to offer a superior and proven dietary supplement for human athleticism and health." He went on to say, "The new patent also offers NAI the ability to move into animal dietary supplementation. This new patent continues the recognition that patented beta-alanine based dietary supplements are uniquely beneficial to humans and animals alike." </p> <p>NAI's new patent contains claims directed, in part, to methods of avoiding or delaying the onset of muscular fatigue through the use of beta-alanine compositions in several formulations. The newly patented methods cover humans as well as certain animals. The methods require the use of beta-alanine that is not part of a dipeptide, polypeptide or oligopeptide and is in the form of a dietary supplement. Esters or amides of beta-alanine, which are not part of a dipeptide, polypeptide or oligopeptide, may also be employed. Additional active agents, such as carbohydrates, L-histidine, insulin and creatine, may also be present. A list of NAI's intellectual property rights may be found at <a href="http://www.carnosyn.com">http://www.carnosyn.com</a>.</p> <p>The only licensed distributor of NAI's CarnoSyn® beta-alanine product is Compound Solutions, Inc., a science and marketing based distributor of raw materials to the sports nutrition, dietary supplement, food, pharmaceutical and personal care industries.</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Wed, 21 Mar 2012 19:40:00 +0000 Natural Alternatives International 36 at http://www.nai-online.com/content Natural Alternatives International, Inc. Settles Patent Infringement Dispute With BPI Sports and Image Sports Over its Patented CarnoSyn(R) Beta-Alanine http://www.nai-online.com/content/?q=node/35 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., March 15, 2012 -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that it has entered into a settlement agreement to provide BPI Sports, LLC ("BPI") and Image Sports, LLC ("Image") with NAI's patented CarnoSyn® beta-alanine.</p> <p>Under the terms of the settlement agreement, BPI and Image will purchase CarnoSyn® beta-alanine from NAI's licensed distributor, Compound Solutions, Inc., ("CSI") pursuant to a separate supply agreement between CSI, BPI and Image and receive a license from NAI to its intellectual property rights regarding CarnoSyn® beta-alanine. </p> <p>Mark A. LeDoux, NAI's CEO and Chairman of the Board, said, "NAI is pleased to amicably resolve its intellectual property dispute with BPI and Image. We look forward to partnering with these prominent brands who chose to respect NAI's extensive beta-alanine patent rights in return for a long-term business solution to exclusively use NAI's CarnoSyn® beta-alanine in their products. NAI will continue to build its CarnoSyn® brand and where necessary, enforce its beta-alanine intellectual property."</p> <p>As part of the agreement NAI will dismiss two cases filed in U.S. District Court for the Southern District of Texas against BPI and Image alleging infringement of NAI's recently issued patent, U.S. Patent No. 8,067,381, entitled "Methods and compositions for increasing the anaerobic working capacity in tissues." BPI and Image will dismiss a counter-suit they filed against NAI in U.S. District Court for the Southern District of Florida. Other terms of the agreement are confidential. A list of NAI's intellectual property rights may be found at <a href="http://www.carnosyn.com">http://www.carnosyn.com</a>.</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Thu, 15 Mar 2012 20:15:00 +0000 Natural Alternatives International 35 at http://www.nai-online.com/content Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc. http://www.nai-online.com/content/?q=node/34 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>SAN MARCOS, Calif., Feb. 14, 2012 -- Natural Alternatives International, Inc. ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that on February 6 it filed a claim for patent infringement against DNP International Co., Inc. in U.S. District Court for the District of Delaware. NAI alleges that DNP infringes U.S. Patent No. 8,067,381 ("the '381 patent"), entitled "Methods and compositions for increasing the anaerobic working capacity in tissues." The '381 patent was issued by the U.S. Patent and Trademark Office on November 29, 2011 and is part of NAI's worldwide portfolio covering CarnoSyn® beta-alanine. DNP becomes the latest in a series of '381 patent infringement claims brought against companies in the nutritional supplement industry, including Woodbolt Distribution, LLC (also known as Cellucor), F.H.G. Corporation (doing business as Integrity Nutraceuticals), Vitaquest International, Inc., (doing business as Garden State Nutritionals), BPI Sports, LLC and Image Sports, LLC.</p> <p>NAI alleges that DNP supplies beta-alanine to nutritional supplement contract manufacturers, formulators and distributors in the United States. DNP imports its beta-alanine into the United States from China. Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "even though DNP has been aware of the new '381 patent since November 30, 2011, it has continued to engage in infringing activities. DNP knows full well that the only duly licensed distributor of NAI's CarnoSyn® beta-alanine product is Compound Solutions, Inc." He went on to say that "NAI will continue to protect and defend its valuable intellectual property portfolio." NAI is represented by the Washington, D.C. based law firm of Patton Boggs LLP.</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI's comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI's clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Tue, 14 Feb 2012 20:00:00 +0000 Natural Alternatives International 34 at http://www.nai-online.com/content Natural Alternatives International, Inc. Announces Fiscal 2012 Q2 Results http://www.nai-online.com/content/?q=node/33 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>Net Sales and Income from Operations Increase 10%</p> <p>SAN MARCOS, Calif., Feb. 13, 2012 -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $785,000 or $0.11 per diluted share on net sales of $16.2 million for the quarter ended December 31, 2011. These results included a full effective tax rate in the second quarter of fiscal 2012 as compared to a lower rate in the prior year period.</p> <p>Net sales for the three months ended December 31, 2011 increased $1.4 million or 9.5% from $14.8 million recorded in the comparable prior year period. For the quarter ended December 31, 2011, contract manufacturing sales increased $1.1 million or 7.5% from the comparable quarter last year due primarily to higher sales to existing customers. Patent and trademark licensing revenue increased to $720,000 or 139% during the quarter ended December 31, 2011 as compared to $301,000 for the prior year period. This licensing revenue was derived through the sale of the ingredient known as beta-alanine sold under our CarnoSyn® trade name. These increases were partially offset by a decline in our branded products sales, which totaled $403,000 for the second quarter of fiscal 2012 as compared to $466,000 for the comparable prior year period. </p> <p>Net sales for the six months ended December 31, 2011 increased to $34.5 million or 22.7% from $28.1 million recorded in the comparable prior year period. Contract manufacturing sales during the first six months of fiscal 2012 increased $5.1 million or 19.3% from the comparable prior year period and patent and trademark licensing revenue increased $1.4 million or 233% during this same period. These increases were partially offset by a decline in our branded products sales, which totaled $804,000 for the first six months of fiscal 2012 as compared to $959,000 for the comparable prior year period. </p> <p>Net income for the first six months of fiscal 2012 totaled $2.3 million or $0.33 per diluted share compared to net income of $1.8 million or $0.25 per diluted share in the comparable prior year period. The increase was primarily attributable to increased contract manufacturing sales and patent and trademark licensing revenue partially offset by increased income tax expense related to the full utilization of our federal net operating loss carryforward during the first quarter of fiscal 2012. </p> <p>As of December 31, 2011, we had cash of $11.2 million and working capital of $26.2 million compared to $15.5 million and $22.9 million, respectively, as of June 30, 2011. As of December 31, 2011, we had $5.5 million available under our line of credit agreements.</p> <p>Mark A. LeDoux, Chairman and Chief Executive Officer commented, "We are pleased to recognize our twelfth consecutive quarter of operational earnings, while remaining debt free since June 2010. We believe we remain poised to secure additional meaningful customer relationships through this fiscal year especially given challenges faced by some of our competitors. The U.S. Food and Drug Administration has expanded its efforts to enforce its federal regulations and standards, and we believe many companies are discovering that they are not adequately prepared to comply with current regulations.</p> <p>"With the addition of our newest U.S. patent in late November 2011, we believe we have also strengthened and expanded our intellectual property estate involving CarnoSyn® beta-alanine. As we seek to expand the value of the estate, we will also continue to actively enforce our patent rights against willful violators. We have every reason to believe the legal system will affirm our patents, and we intend to continue to enforce our patent rights against those persons or firms who infringe upon them."</p> <p>NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at <a href="http://www.nai-online.com">http://www.nai-online.com</a>.</p> <p>This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, our ability to expand our contract manufacturing business and patent estate, comply with Good Manufacturing Practices and other applicable regulations and standards, improve stockholder value, remain debt free, develop, maintain or increase sales to new and existing customers, and successfully maintain and enforce our intellectual property rights, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.</p> </div></div></div> Mon, 13 Feb 2012 20:45:00 +0000 Natural Alternatives International 33 at http://www.nai-online.com/content U.S. Ambassador to Switzerland visits NAIE http://www.nai-online.com/content/?q=node/32 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>Ambassador Beyer and Commercial Specialist Sandor Galambos met with Director Dr. Fausto Petrini and his team at Natural Alternatives International Europe SA (NAIE) in Manno. </p> <p><a href="http://bern.usembassy.gov/visits_12152011.html">http://bern.usembassy.gov/visits_12152011.html</a></p> </div></div></div> Mon, 06 Feb 2012 17:22:59 +0000 Natural Alternatives International 32 at http://www.nai-online.com/content 'There are more infringing companies out there', says lawyer in latest beta-alanine patent lawsuits http://www.nai-online.com/content/?q=node/31 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>The three firms that have now been hit with a patent infringement lawsuit filed by Natural Alternatives International (NAI) are not the only ones allegedly infringing NAI’s newly-granted patent regarding sports nutrition ingredient beta-alanine, claims a lawyer acting for NAI.</p> <p><a href="http://www.nutraingredients-usa.com/Regulation/There-are-more-infringing-companies-out-there-says-lawyer-in-latest-beta-alanine-patent-lawsuits">http://www.nutraingredients-usa.com/Regulation/There-are-more-infringing...</a></p> </div></div></div> Wed, 25 Jan 2012 16:00:00 +0000 Natural Alternatives International 31 at http://www.nai-online.com/content